Rachael Gross, DO
Family Medicine · Orangeburg, SCNPI 1467438853
Payments from drug & device makers
Across 237 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$657
- AstraZeneca$460
- AbbVie$345
- Lilly USA, LLC$306
- Bayer$217
- Takeda Pharmaceuticals U.S.A., Inc.$198
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $657 |
| AstraZeneca | 28 | $460 |
| AbbVie(2 entities) | 28 | $345 |
| Lilly USA, LLC | 18 | $306 |
| Bayer | 12 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $198 |
| GSK | 11 | $171 |
| Boehringer Ingelheim | 9 | $149 |
| Amgen | 9 | $136 |
| Merck | 9 | $130 |
| Corcept Therapeutics | 6 | $114 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| Ardelyx, Inc. | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Johnson & Johnson | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Exact Sciences | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Eisai Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Pfizer | 3 | $43 |
| Mylan Specialty L.p. | 3 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Dexcom, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Novartis | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,754 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $95,912 |
| OzempicSemaglutide | 79 | $89,769 |
| MounjaroTirzepatide | 72 | $88,008 |
| JardianceEmpagliflozin | 87 | $69,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $65,869 |
| RybelsusSemaglutide | 49 | $55,086 |
| FarxigaDapagliflozin Propanediol | 63 | $52,476 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 63 | $44,638 |
| XareltoRivaroxaban | 39 | $37,635 |
| KerendiaFinerenone | 32 | $27,829 |
| JanumetSitagliptin Phos/Metformin Hcl | 29 | $25,751 |
| LinzessLinaclotide | 45 | $25,010 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $24,695 |
| JanuviaSitagliptin Phosphate | 26 | $24,554 |
| MyrbetriqMirabegron | 36 | $22,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $657 | $144,855128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $306 | $108,00989 claims |
| Boehringer IngelheimJardiance, Glyxambi, Jentadueto Xr, Spiriva Respimat, Synjardy Xr | $149 | $105,873145 claims |
| PfizerEliquis, Premarin | $43 | $100,517122 claims |
| MerckJanumet Xr, Janumet, Januvia | $130 | $94,944118 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $460 | $82,601115 claims |
| GSKTrelegy Ellipta | $171 | $65,86979 claims |
| Johnson & JohnsonXarelto | $65 | $37,63539 claims |
| BayerKerendia | $217 | $27,82932 claims |
| AbbVieLinzess | $345 | $25,01045 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $22,94436 claims |
| NovartisEntresto | $15 | $22,60024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Orangeburg
- Monnieque SingletonOrangeburg$34K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.